Skip to main content
60°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exelixis Inc
(NQ:
EXEL
)
25.88
+0.10 (+0.39%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Exelixis Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
More Chinese Trouble
October 14, 2021
A day after the consumer price rise there was another price rise for producer markets.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
October 07, 2021
Upgrades For State Street Corporation (NYSE:
Via
Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
July 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...
Via
Benzinga
Exposures
COVID-19
Exelixis's Cabometyx Scores FDA Nod In Differentiated Thyroid Cancer; ESMO Presentation
September 20, 2021
The FDA has approved Exelixis Inc's (NASDAQ: EXEL) Cabometyx (cabozantinib) for thyroid cancer in patients aged 12 years and older. The approval covers...
Via
Benzinga
Exposures
Product Safety
A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street; Crude Oil Down 2%
September 20, 2021
Pre-open movers U.S. stock futures traded sharply lower in early pre-market trade after recording losses in the previous session. Investors are awaiting earnings results from...
Via
Benzinga
Exposures
Fossil Fuels
Exelixis' Cabometyx Combo Trial Shows Benefit In Kidney Cancer Regardless Of Prior Surgery
September 16, 2021
Exelixis Inc (NASDAQ: EXEL) has announced results demonstrating efficacy benefits of Cabometyx (cabozantinib) in patients with previously untreated advanced renal...
Via
Benzinga
2 Top Biotech Stocks to Buy Right Now
September 11, 2021
Both have underperformed the market recently. And both are primed for a comeback.
Via
The Motley Fool
Is Exelixis Stock a Buy?
September 02, 2021
This biotech stock is down, but it's not out just yet.
Via
The Motley Fool
Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer
August 26, 2021
Exelixis Inc's (NASDAQ: EXEL) collaborating partner Takeda Pharmaceutical Co Ltd (NYSE: TAK) and Ono Pharmaceutical Co Ltd have received...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
August 17, 2021
Gainers Celularity (NASDAQ:CELU) shares rose 7.0% to $7.33 during Tuesday's after-market session. The market value of their outstanding shares is at $904.9...
Via
Benzinga
Exelixis, Invenra Expand Oncology Pact
August 16, 2021
Exelixis Inc (NASDAQ: EXEL) and Invenra have expanded their discovery and licensing collaboration to include 20 additional oncology targets. The augmented...
Via
Benzinga
Exelixis, inc (EXEL) Q2 2021 Earnings Call Transcript
August 06, 2021
EXEL earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Recap: Exelixis Q2 Earnings
August 05, 2021
Shares of Exelixis (NASDAQ:EXEL) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 48.00% year over year...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
August 05, 2021
Gainers Sensus Healthcare (NASDAQ:SRTS) ...
Via
Benzinga
Exelixis Files US Application For Expanded Use Of Cabometyx In Patients 12+ Years With Thyroid Cancer
August 05, 2021
The FDA has accepted Exelixis Inc's (NASDAQ: EXEL) supplemental marketing application seeking approval for Cabometyx (cabozantinib) for differentiated thyroid...
Via
Benzinga
Exposures
Product Safety
5 No-Brainer Stocks to Invest $500 In Right Now
July 26, 2021
You don't need a mountain of cash to build wealth on Wall Street.
Via
The Motley Fool
The Smartest Stocks to Buy With $20 in July
July 16, 2021
You don't need a lot of cash to begin or further your trek toward financial independence.
Via
The Motley Fool
Analyzing Exelixis's Unusual Options Activity
July 12, 2021
Shares of Exelixis (NASDAQ:EXEL) saw some unusual options activity on Monday. Following the unusual option alert, the stock price moved down to $17.64. Sentiment: BULLISH Option...
Via
Benzinga
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
July 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated...
Via
Benzinga
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
July 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15) IVERIC bio, Inc. (NASDAQ:...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
July 15, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals,...
Via
Benzinga
Topics
Product Recall
Exposures
Legal
Product Safety
Stocks That Hit 52-Week Lows On Wednesday
July 14, 2021
Wednesday morning saw 57 companies set new 52-week lows. Noteworthy Points: Campbell Soup (NYSE:CPB) was the largest firm by market cap to set a new 52-week low....
Via
Benzinga
After Plummeting More Than 23%, Is Exelixis a Buy?
July 09, 2021
The market may have overreacted to weak clinical trial data, but its pessimism wasn't entirely misplaced.
Via
The Motley Fool
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
July 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc...
Via
Benzinga
Is Exelixis Stock a Buy After Its Disappointing Liver Cancer Study Results?
July 09, 2021
The biotech stock plunged after disappointing clinical results.
Via
The Motley Fool
Fireworks Display
July 05, 2021
The oil price rose to 76.81/bbl after the OPEC attempt to have a meeting to agree to boost production (and cut prices) was blocked.
Via
Talk Markets
End Of June
June 30, 2021
Canadian Solar fell 4.6% on fears of plans for a China IPO where its panels are made.
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
July 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:...
Via
Benzinga
Topics
Product Recall
Exposures
COVID-19
Legal
Product Safety
The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs
June 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) 10x Genomics, Inc. (NASDAQ...
Via
Benzinga
June’s Best and Worst Performing Russell 1,000 Stocks
June 29, 2021
The month of June, the second quarter and the first half of 2021 are almost in the bag.
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.